Skip to main content
TipRanks
Go Ultimate75% OFF

LABORATORIO REIG JOFRE (0RB1) Share Price & Analysis

0 Followers

0RB1 Stock Chart & Stats

€2.61-€0.02(-0.95%)
At close: 4:30 PM GMT
€2.5€2.6€2.7Aug 21Sep 8Sep 18Oct 2Oct 16Nov 2Nov 16
Day’s Range
EUR 2.60 - EUR 2.61
52-Week Range
EUR 2.34 - EUR 2.82
Previous Close
EUR 2.63
Volume
N/A
Average Volume (3M)
26
Market Cap
EUR 214.07M
Enterprise Value
EUR 329.17M
Total Cash (Recent Filing)
EUR 14.78M
Total Debt (Recent Filing)
EUR 119.58M
Price to Earnings (P/E)
30.7
Beta
0.24
Next Earnings
Feb 26, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
0.75%

Bulls Say, Bears Say

Bulls Say

Diversified Pharmaceutical Model

The combination of proprietary pharmaceutical products and CDMO services gives RJF more than one route to revenue. Its own portfolio can support product-led growth, while outsourced development and manufacturing use existing capabilities to broaden customer and market exposure.

Moderate Balance-sheet Leverage

Historically moderate leverage and gradual equity growth provide a degree of financial resilience for a pharmaceutical manufacturer. This balance-sheet foundation can support ongoing operations and selective investment, even though leverage increased in the latest year.

Prior Operating Track Record

The pre-2025 record shows that RJF had established revenue momentum and relatively consistent EBITDA margins over several years. That history indicates an operating platform capable of producing durable growth and profitability when conditions are supportive.

Bears Say

Sharp 2025 Revenue Contraction

The 2025 revenue decline represents a material interruption to RJF’s earlier growth trajectory. A contraction of this scale can reduce operating leverage, weaken absorption of fixed costs, and make recovery in earnings dependent on renewed demand or improved pricing.

Severe Cash-flow Deterioration

Negative free cash flow and sharply lower operating cash generation weaken RJF’s ability to fund investment and obligations internally. The volatility, including prior negative free cash flow in 2021, makes cash conversion less dependable over the medium term.

Profitability And Returns Weakened

The collapse in operating and net margins leaves limited earnings cushion if costs or commercial pressure persist. Lower ROE also indicates that the enlarged equity base is currently generating modest returns, reducing the company’s ability to compound shareholder value efficiently.

LABORATORIO REIG JOFRE News

0RB1 FAQ

What was LABORATORIO REIG JOFRE’s price range in the past 12 months?
LABORATORIO REIG JOFRE lowest share price was €2.34 and its highest was €2.82 in the past 12 months.
What is LABORATORIO REIG JOFRE’s market cap?
LABORATORIO REIG JOFRE’s market cap is €214.07M.
When is LABORATORIO REIG JOFRE’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were LABORATORIO REIG JOFRE’s earnings last quarter?
LABORATORIO REIG JOFRE released its earnings results on Jul 31, 2026. The company reported €0.005 earnings per share for the quarter.
Is LABORATORIO REIG JOFRE overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does LABORATORIO REIG JOFRE pay dividends?
LABORATORIO REIG JOFRE does not currently pay dividends.
What is LABORATORIO REIG JOFRE’s EPS estimate?
LABORATORIO REIG JOFRE’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LABORATORIO REIG JOFRE have?
LABORATORIO REIG JOFRE has 82,883,400 shares outstanding.
What happened to LABORATORIO REIG JOFRE’s price movement after its last earnings report?
LABORATORIO REIG JOFRE reported an EPS of €0.005 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of LABORATORIO REIG JOFRE?
Currently, no hedge funds are holding shares in GB:0RB1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology